Abstract:L. donovani and L. infantum infections are associated with a broad clinical spectrum, ranging from asymptomatic cases to visceral leishmaniasis (VL) with high mortality rates. Clinical manifestations such as post-kala-azar dermal leishmaniasis (PKDL) and visceral leishmaniasis-associated hemophagocytic lymphohistiocytosis-mimic (VL-associated HLH-mimic) further contribute to the diversity of clinical manifestations. These clinical variations are intricately influenced by the complex interplay between the host's immune response and the parasite's escape mechanisms. This narrative review aims to elucidate the underlying immunological mechanisms associated with each clinical manifestation, drawing from published literature within the last 5 years. Specific attention is directed toward viscerotropic Leishmania sinfection in patients with inborn errors of immunity and acquired immunodeficiencies. In VL, parasites exploit various immune evasion mechanisms, including immune checkpoints, leading to a predominantly anti-inflammatory environment that favors parasite survival. Conversely, nearly 70% of individuals are capable of mounting an effective pro-inflammatory immune response, forming granulomas that contain the parasites. Despite this, some patients may experience reactivation of the disease upon immunosuppression, challenging current understandings of parasite eradication. Individuals living with HIV and those with inborn errors of immunity present a more severe course of infection, often with higher relapse rates. Therefore, it is crucial to exclude both primary and acquired immune deficiencies in patients presenting disease relapse and VL-associated HLH-mimic. The distinction between VL and HLH can be challenging due to clinical similarities, suggesting that the nosological entity known as VL-associated HLH may represent a severe presentation of symptomatic VL and it should be considered more accurate referring to this condition as VL-associated HLH-mimic. Consequently, excluding VL in patients presenting with HLH is essential, as appropriate antimicrobial therapy can reverse immune dysregulation. A comprehensive understanding of the immune-host interaction underlying Leishmania infection is crucial for formulating effective treatment and preventive strategies to mitigate the disease burden.

A Review of Leishmaniasis: Current Knowledge and Future Directions

A review on potential therapeutic targets for the treatment of leishmaniasis

Revolutionizing Leishmaniasis Treatment with Cutting Edge Drug Delivery Systems and Nanovaccines: An Updated Review

From infection to vaccination: reviewing the global burden, history of vaccine development, and recurring challenges in global leishmaniasis protection

Advances in Leishmania Vaccines: Current Development and Future Prospects

Tackling Drug Resistance and Other Causes of Treatment Failure in Leishmaniasis

Immunotherapeutic Strategies as Potential Treatment Options for Cutaneous Leishmaniasis

Leishmania vaccine development: A comprehensive review

Current and emerging therapies for the treatment of leishmaniasis

Vaccine candidates against leishmania under current research

Exploring Bioinformatics Solutions for Improved Leishmaniasis Diagnostic Tools: A Review

Review on the Drug Intolerance and Vaccine Development for the Leishmaniasis

Leishmaniasis – Still a diagnostic challenge: An individual participant data systematic review

Recent Advances in the Treatment of Leishmaniasis

Compounds with potentialities as novel chemotherapeutic agents in leishmaniasis at preclinical level

Anti-trypanosomatid drug discovery: progress and challenges

Immune response to viscerotropic Leishmania: a comprehensive review

Leishmania, microbiota and sand fly immunity

Canine Leishmaniasis: An Overview of the Current Status and Strategies for Control

Cutaneous leishmaniasis in sub-Saharan Africa: a systematic review of Leishmania species, vectors and reservoirs

Non-Endemic Leishmaniases Reported Globally in Humans between 2000 and 2021—A Comprehensive Review